2018
PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs.
Morris M, Vogelzang N, Sartor A, Armour A, Messmann R, Groaning M, Robarts A, Tolcher A, Gordon M, Babiker H, Kuo P, Kearney M, Jendrisak A, Wang Y, Landers M, Petrylak D. PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs. Journal Of Clinical Oncology 2018, 36: 272-272. DOI: 10.1200/jco.2018.36.6_suppl.272.Peer-Reviewed Original ResearchMetastatic castrate-resistant prostate cancerProstate-specific membrane antigenSPECT/CT scansHomologous recombination deficiency scoresPSMA expressionProstate cancerCT scanPre-treatment blood samplesDeficiency scoresCastrate-resistant prostate cancerBiomarker analysisSoft tissue lesionsSPECT/CTTherapeutic predictive valueDetectable CTCsNaïve patientsBone scanBad respondersClinical outcomesBaseline CTBone lesionsPositive lesionsBlood samplesTissue lesionsTherapeutic target
2009
Correlation of progression-free survival (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) who failed first-line chemotherapy: Results from the SPARC Trial
Halabi S, Sartor O, Petrylak D, Sternberg C, Witjes J, Noursalehi M, McKearn T, George M. Correlation of progression-free survival (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) who failed first-line chemotherapy: Results from the SPARC Trial. Journal Of Clinical Oncology 2009, 27: 5150-5150. DOI: 10.1200/jco.2009.27.15_suppl.5150.Peer-Reviewed Original ResearchProgression-free survivalCastration-resistant prostate cancerFirst-line chemotherapyOverall survivalMetastatic castration-resistant prostate cancerChemotherapy-naïve patientsDouble-blind trialDate of randomizationMedian survival timePredictors of OSProportional hazards modelType of progressionSPARC trialLine chemotherapyCRPC patientsNaïve patientsFirst progressionTau measuresProstate cancerLandmark analysisSurvival timeTreatment groupsHazards modelStratification factorsClinical relevance